In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo.
https://www.nature.com/articles/s41591-025-04090-y

Thank you Elisa Martini for featuring the IVORY trial published in @natmed.nature.com in Nature Portfolio’s Nature CVR 🫀

Main paper: rdcu.be/eX8W3
Commentary: rdcu.be/eYyG6

@jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social

Thank you @vpd-hlri.bsky.social for the shout-out.
Original article here:

rdcu.be/eX8W3

The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3

This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a
⬆️ Regulatory T cells
⬇️ Arterial inflammation 🔥
⬇️ trend in adverse cardiovascular outcomes ❤️‍🔥 at 2 years

PAPER ALERT: The IVORY trial published in Nature Medicine last week: rdcu.be/eX8W3

@ziadmallat.bsky.social @vpd-hlri.bsky.social @nihr.bsky.social @cuh.nhs.uk @royalpapworth.bsky.social @inserm.fr @parcc-inserm.bsky.social @medcambridge.bsky.social @rouchelles.bsky.social @jc403.bsky.social

Amazing work by @rouchelles.bsky.social & Co. Prions of this team!

Nature Medicine: rdcu.be/eX8W3

Thank you @danieljdrucker.bsky.social for highlighting our work. This may be a game changer!

Nature Medicine: rdcu.be/eX8W3

Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation.
Learn More: www.nature.com/articles/s41...

Original article:
rdcu.be/eX8W3